BioMarin Pharmaceutical Inc.
776 articles with BioMarin Pharmaceutical Inc.
-
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
3/17/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in the New England Journal of Medicine (NEJM).
-
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
2/23/2022
BioMarin Pharmaceutical Inc. announced financial results for the fourth quarter and full-year ended December 31, 2021.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
Biomarin indicated that the FDA had requested more data from non-clinical studies to evaluate the theoretical cancer risk to human trial participants. This is likely to take several quarters.
-
BioMarin Provides Updates on Progress in Gene Therapy Programs
2/17/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development.
-
BioMarin to Participate in Two Upcoming Virtual Investor Conferences - Feb 16, 2022
2/16/2022
BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.
-
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET
2/10/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 23rd, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and provide a general business update.
-
BioMarin Sells Priority Review Voucher for $110 Million
2/9/2022
BioMarin Pharmaceutical Inc. announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher it obtained in November 2021 for a lump sum payment of $110,000,000.
-
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
-
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February
2/4/2022
BioMarin Pharmaceutical Inc. today announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study.
-
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4
2/2/2022
BioMarin Pharmaceutical Inc. announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders February 2-4.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
The results over the two-year evaluation period for its Phase III GENEr8-1 trial showed consistent clinical benefit from using valoctocogene roxaparvovec.
-
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis
1/9/2022
BioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc. announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
BioMarin to Participate in Two Virtual Investor Conferences in January 2022
1/4/2022
BioMarin Pharmaceutical Inc. announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two virtual conferences in January.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
12/16/2021
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing novel treatments for unmet medical needs, today announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus (AAV) gene therapies to treat genetic cardiovascular diseases.
-
BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors
12/15/2021
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022.
-
BioMarin to Hold Virtual R&D Day at 11:00am ET Today
11/30/2021
BioMarin Pharmaceutical Inc. will host a virtual R&D Day beginning at 8:00am PT/11:00am ET , Tuesday, November 30, 2021.